MREO Stock Summary and Trading Ideas (Mereo Biopharma Group PLC - American Depositary Shares | NASDAQ:MREO)

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Mereo Biopharma Group PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol MREO.

As of September 2, 2026, MREO stock price declined to $0.27 with 518,414 million shares trading.

MREO has a beta of 2.74, meaning it tends to be more sensitive to market movements. MREO has a correlation of 0.04 to the broad based SPY ETF.

MREO has a market cap of $43.10 million. This is considered a Sub-Micro Cap stock.

Last quarter Mereo Biopharma Group PLC - American Depositary Shares reported $0 in Revenue and -$.01 earnings per share. This fell short of revenue expectation by $-863,830 and met earnings estimates .

In the last 3 years, MREO traded as high as $5.02 and as low as $.20.

The top ETF exchange traded funds that MREO belongs to (by Net Assets): GWX.

MREO has underperformed the market in the last year with a price return of -84.2% while the SPY ETF gained +19.8%. MREO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -12.3% and -13.7%, respectively, while the SPY returned +1.1% and -0.3%, respectively.

MREO support price is $.26 and resistance is $.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MREO shares will trade within this expected range on the day.